{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:52:40Z","timestamp":1775947960037,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung transplant recipients (LTRs) frequently receive off\u2010label inhaled tobramycin. However, LTRs differ pharmacokinetically from cystic fibrosis (CF) patients for whom the drug is approved and may be at increased risk for toxic systemic concentrations. This study characterized the incidence and predictors of detectable serum tobramycin concentrations among LTRs without underlying CF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single\u2010center cohort study included LTRs receiving inhaled tobramycin (without intravenous\/intramuscular tobramycin) with serum concentration testing July 2015 to June 2025. Logistic regression identified predictors of elevated concentrations (tobramycin \u2265\u00a01\u00a0\u00b5g\/mL), and analysis of covariance evaluated the dose\/concentration relationship controlled for timing. Acute kidney injury (AKI) was defined as \u2265\u00a00.3\u00a0mg\/dL or a 1.5\u00d7 increase in serum creatinine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty\u2010four LTRs (median age 69\u00a0years [IQR: 63\u201372]) contributed 56 tobramycin concentrations; 93% were inpatients, and 9% required renal replacement therapy (RRT). Inhaled tobramycin was dosed 160\u00a0mg (59%) or 300\u00a0mg (41%) twice daily. Detectable tobramycin serum concentrations occurred in 80% of patients (median 0.4\u00a0\u00b5g\/mL [IQR: 0.3\u20130.8]); 8 (18%) had concentrations \u2265\u00a01\u00a0\u00b5g\/mL, and 3 (7%) \u2265\u00a02\u00a0\u00b5g\/mL. The 300\u00a0mg dose was associated with elevated concentrations (OR 7.2, 95% CI: 1.1\u201349.2,\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      =\u00a00.043), including after adjusting for concentration timing (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). Among non\u2010RRT patients, 55% developed new AKI a median of 3\u00a0days after concentration sampling, with tobramycin concentrations significantly higher in the AKI group (0.4\u00a0\u00b5g\/mL vs. 0.2\u00a0\u00b5g\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.035).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LTRs without CF commonly had systemic tobramycin exposure during inhaled therapy. The 300\u00a0mg dose was linked to higher serum concentrations, supporting reduced dosing and active serum concentration monitoring to enhance safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/tid.70158","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T18:52:30Z","timestamp":1766775150000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhaled Tobramycin Dose and Systemic Absorption in Lung Transplant Recipients Without Cystic Fibrosis"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9736-0891","authenticated-orcid":false,"given":"Kellie J.","family":"Goodlet","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice Midwestern University College of Pharmacy  Glendale Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Nailor","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3207-9089","authenticated-orcid":false,"given":"Amanda","family":"Hodges","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Midwestern University College of Pharmacy  Glendale Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-8776","authenticated-orcid":false,"given":"Sofya","family":"Tokman","sequence":"additional","affiliation":[{"name":"Division of Transplant Pulmonology Norton Thoracic Institute Dignity Health St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.1.219"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1836157"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000044"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2004.05.008"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2005.10.008"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2022.101584"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201311\u2010395FR"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac412"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.12579"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.09412"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1179548420930925"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399\u20103062.2011.00651.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010015\u20101854\u20107"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2016.1214885"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00424\u201016"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.70158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tid.70158","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.70158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:41:23Z","timestamp":1775947283000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.70158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/tid.70158"],"URL":"https:\/\/doi.org\/10.1111\/tid.70158","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"2025-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70158"}}